A Phase 3 interventional study of AA4500 in Advanced Dupuytren's Disease, sponsored by Endo Pharmaceuticals. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-02.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study AUX-CC-858 was an open-label continuation of the double-blind Study AUX-CC-857 (NCT00528606). Subjects who complete the Day 90 visit after their initial injection in Study AUX-CC-857 (NCT00528606) entered into Study AUX-CC-858. Subjects who required further treatment in Study AUX-CC-858, either because their treated metacarpophalangeal and/or proximal interphalangeal (PIP) joints did not have a reduction in contracture to 5° or less, the cord affecting that joint received less than three injections of AA4500, or they had other eligible cords that received no treatment in AUX-CC-857 (NCT00528606), had the option to receive up to five injections of AA4500 in this extension study. Subjects requiring further treatment were followed for efficacy and safety on Days 1, 7, and 30 after each injection, with injections separated by four weeks. Follow-up visits for the determination of efficacy and safety were conducted on Day 90, Month 6, and Month 9.
This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 (NCT00528606) and AUX-CC-859 (NCT00533273)) and 7 non-pivotal studies were evaluated.
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: AA4500
Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.
Also known as: XIAFLEX®
Reduction in Contracture to 5° or Less
Successfully treated or clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
Time frame: Within 30 days after last injection
Clinical Improvement After the Last Injection
Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
Time frame: Baseline, within 30 days after last injection
Percent Reduction From Baseline Contracture After the Last Injection
Percent change in degree of contracture in non-primary joints measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture.
Time frame: Baseline, Day 30 after last injection
Change From Baseline Range of Motion After the Last Injection
Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion
Time frame: Baseline, Day 30 after last injection
Time to Reach Clinical Success
Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories
Time frame: Within 30 days after last injection
Clinical Success After the First Injection
Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
Time frame: Within 30 days after first injection
Clinical Improvement After the First Injection
Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
Time frame: Baseline, within 30 days after first injection
Percent Reduction From Baseline Contracture After the First Injection
Percent change in degree of contracture in non-primary joints measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture.
Time frame: Baseline, Day 30 after first injection
Change From Baseline Range of Motion After the First Injection
Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion
Time frame: Baseline, Day 30 after first injection
| Milestone | AA4500 0.58 mg |
|---|---|
| Started | 286 |
| Completed | 257 |
| Not completed | 29 |
| Withdrew: Lost to follow-up | 13 |
| Withdrew: Withdrew consent | 2 |
| Withdrew: Administrative reason | 2 |
| Withdrew: Other | 12 |
Successfully treated or clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
| Percentage of joints | AA4500 0.58 mg |
|---|---|
| Reduction in Contracture to 5° or Less | 41.9 |
Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
| Percentage of joints | AA4500 0.58 mg |
|---|---|
| Clinical Improvement After the Last Injection | 65.0 |
Percent change in degree of contracture in non-primary joints measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture.
| Percentage of change | AA4500 0.58 mg |
|---|---|
| Percent Reduction From Baseline Contracture After the Last Injection | 60.8 ± 39.00 |
Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion
| Degrees | AA4500 0.58 mg |
|---|---|
| Change From Baseline Range of Motion After the Last Injection | 24.0 ± 20.83 |
Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories
| Percentage of Joints | AA4500 0.58 mg |
|---|---|
| Injection 1, Day 1 | 12.5 |
| Injection 1, Day 7 | 15.9 |
| Injection 1, Day 30 | 5.9 |
| Injection 2, Day 0 | 0.0 |
| Injection 2, Day 1 | 2.2 |
| Injection 2, Day 7 | 1.3 |
| Injection 2, Day 30 | 1.9 |
| Injection 3, Day 0 | 0.0 |
| Injection 3, Day 1 | 1.3 |
| Injection 3, Day 7 | 0.6 |
| Injection 3, Day 30 | 0.3 |
| Did not reach Clinical Success | 58.1 |
Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
| Percentage of Joints | AA4500 0.58 mg |
|---|---|
| Clinical Success After the First Injection | 34.1 |
Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
| Percentage of Joints | AA4500 0.58 mg |
|---|---|
| Clinical Improvement After the First Injection | 56.3 |
Percent change in degree of contracture in non-primary joints measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture.
| Percentage of change | AA4500 0.58 mg |
|---|---|
| Percent Reduction From Baseline Contracture After the First Injection | 53.9 ± 38.64 |
Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion
| Degrees | AA4500 0.58 mg |
|---|---|
| Change From Baseline Range of Motion After the First Injection | 20 ± 19.46 |
Collected over From the time of study drug administration until 30 days after completion of or discharge from the study. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AA4500 0.58 mg | — | 9/286 (3.1%) | 171/286 (59.8%) |
| Event | AA4500 0.58 mg |
|---|---|
| Abdominal painGastrointestinal disorders | 1/286 |
| Acute myocardial infarctionCardiac disorders | 1/286 |
| AstheniaGeneral disorders | 1/286 |
| Chronic myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/286 |
| Clostridial infectionInfections and infestations | 1/286 |
| Finger deformityMusculoskeletal and connective tissue disorders | 1/286 |
| MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/286 |
| NauseaGastrointestinal disorders | 1/286 |
| NephrolithiasisRenal and urinary disorders | 1/286 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/286 |
| Event | AA4500 0.58 mg |
|---|---|
| Oedema peripheralGeneral disorders | 136/286 |
| ContusionInjury, poisoning and procedural complications | 95/286 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 66/286 |
| Injection site haemorrhageGeneral disorders | 52/286 |
| Injection site painGeneral disorders | 47/286 |
| TendernessGeneral disorders | 43/286 |
| EcchymosisSkin and subcutaneous tissue disorders | 39/286 |
| Injection site swellingGeneral disorders | 34/286 |
| PruritusSkin and subcutaneous tissue disorders | 33/286 |
| Skin lacerationInjury, poisoning and procedural complications | 24/286 |
| Age, Categorical(Participants) | AA4500 0.58 mg |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 166 |
| >=65 years | 120 |
| Age, Continuous(years) | AA4500 0.58 mg |
|---|---|
| Mean | 62.7 ± 9.5 |
| Sex: Female, Male(Participants) | AA4500 0.58 mg |
|---|---|
| Female | 60 |
| Male | 226 |
| Race/Ethnicity, Customized(participants) | AA4500 0.58 mg |
|---|---|
| White | 285 |
| Hispanic | 1 |
| Region of Enrollment(participants) | AA4500 0.58 mg |
|---|---|
| United States | 286 |
Ran from Dec 2007 to primary completion in Nov 2008, 11 months.
Results were first posted in Oct 2010, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase